Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22691905 | 1.00 | KMT2A (0.53) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL29401148 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL29569815 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL29850382 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL13401519 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL25356641 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL119468 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL31647336 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL29362229 | 0.92 | KMT2A (0.55) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL14546586 | 0.91 | KMT2A (0.51) | KMT2ATLR2MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4251209-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230091510-A1 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972650-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | KMT2A 752/4885TLR2 4594/4885MDM4 978/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | KMT2A 2654/4885TLR2 885/4885MDM4 4129/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | KMT2A 719/4885TLR2 4179/4885MDM4 282/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | KMT2A 457/4885TLR2 3483/4885MDM4 669/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | KMT2A 2434/4885TLR2 1153/4885MDM4 4312/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | KMT2A 2058/4885TLR2 4306/4885MDM4 682/4885 |
| US-20230091510-A1 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | CD44, IGSF11, ABCC1 | KMT2A 1612/4885TLR2 2021/4885MDM4 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.